October 7, 2021
The Alliance of Community Health Plans (ACHP) appreciates the Administration’s willingness to engage industry partners regarding the recently FDA-approved Alzheimer’s drug, Aduhelm. ACHP shares concerns raised by many stakeholders regarding the lack of clinical evidence demonstrating value of the drug, use of beta-amalyloid plaques as a surrogate endpoint and patient safety. Below are recommendations ACHP submitted to the Centers for Medicare and Medicaid Services (CMS) as it considers coverage for Aduhelm.
Learn How ACHP is Championing Lower Drug Costs
Learn How ACHP Members are Fighting to Make Health Care Better
All media inquiries should be directed to: